Putnam Associates Study Finds Insurers Want More Prescription Drug Use

Putnam Associates released today the results of an intensive study of U.S. health insurance plans' perceptions of branded prescription drug use in the U.S. The study revealed that plans believe greater pharmacoeconomic value can be unlocked by increasing patient use within certain drug categories.

Rising healthcare expenses have insurance companies desperate to cut costs, and many worry this will prompt increasing restrictions across the board on patient prescription drug coverage. However, Putnam discovered 8 classes of drugs, accounting for over $100 billion in sales, where insurers believe that increasing the number of patients on therapies and getting those patients with prescriptions to take their drugs would create value for both patients and plans in the long term.

Plans' interest in seeing increased appropriate use suggests there is opportunity for pharmaceutical manufacturers to align with them on certain drug categories. "The common ground between health plans and pharmaceutical manufacturers is around appropriate use, as these conversations can unlock value and address needs for both parties," says Richard Tinsley, Partner at Putnam Associates. He adds, "Our study shows there is clear agreement and opportunity for expanded appropriate use in many categories while in others there is less agreement. One of the key challenges for a managed markets team is how to address these issues at a portfolio level."

Putnam Associates researchers spoke to health care plan decision-makers who collectively insure 62% of the privately insured U.S. population, or roughly 124 million individuals. Insurers were asked to consider both underuse and over use of branded prescription drugs across 18 drug categories. Of the 18 categories, 8 were identified as being underused.

To download a copy of "U.S. Managed Markets: Opportunities and Risks in the Emerging Appropriate Use Paradigm" visit http://www.putassoc.com/company/pub_usmanaged.html

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]